What happened
Sainuo Medical announced on Sept. 3 that it held an investor research session on Sept. 1. The company was represented by Chairman and General Manager Sun Jianhua, Director and Board Secretary Huang Kai, independent directors Li Rui, Li Hui, and Ma Yuanju, and CFO Shen Lihua.
During the Q&A portion, a shareholder cited half-year report figures showing overseas operating revenue of 23,362,472.03 yuan, which supposedly already accounts for 80% of the company's full-year 2025 overseas revenue. The shareholder asked what caused the rapid growth in first-half overseas revenue, what work management had done, and also began asking about the second-half overseas market outlook.
Why it matters
The focus on overseas revenue suggests investors are closely watching Sainuo Medical's international expansion as a growth driver. A single half-year result reaching around four-fifths of a full-year overseas revenue figure would understandably draw attention from investors evaluating management's performance.
The conspicuous presence of senior executives, including the chairman, CFO, board secretary, and two independent directors, indicates that capital markets communication is being taken seriously, even if only a limited portion of the Q&A has been disclosed.
Key facts
Sainuo Medical announced on Sept. 3 that it hosted investor research on Sept. 1.
Attendees included Chairman Sun Jianhua, Director and Board Secretary Huang Kai, independent directors Li Rui, Li Hui, and Ma Yuanju, and CFO Shen Lihua.
A shareholder question referenced first-half overseas operating revenue of 23,362,472.03 yuan, said to represent 80% of full-year 2025 overseas revenue.
What to watch next
The full PDF of the Q&A may contain management's specific explanation of what drove the overseas revenue increase and which markets or products contributed.
Investors will likely watch for any follow-up disclosures or announcements that clarify whether the strong H1 overseas performance can be sustained in the second half of the year.